<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03792100</url>
  </required_header>
  <id_info>
    <org_study_id>SMKV-015-CP3</org_study_id>
    <nct_id>NCT03792100</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of SmofKabiven Emulsion for Infusion Versus Hospital Compounded Emulsion &quot;All in One&quot; for Parenteral Nutrition</brief_title>
  <official_title>Efficacy and Safety of SmofKabiven Emulsion for Infusion [Multi-oil Fat Emulsion (C6-24)/Amino Acids (16)/Glucose (42%) and Electrolyte Injection] Versus Hospital Compounded Emulsion &quot;All in One&quot; for Parenteral Nutrition: A Randomized, Active-Controlled, Patient-blinded, Multi-Centre Study in Adult Surgical Patients Requiring Parenteral Nutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fresenius Kabi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present protocol describes a randomized, patient-blinded study in which either
      SmofKabiven emulsion for infusion or a hospital compounded &quot;All in one&quot; control Total
      Parenteral Nutrition (TPN) regimen will be given to adult surgical patients for 5 consecutive
      days. As serum prealbumin is a well-established surrogate efficacy parameter reflecting the
      patientÂ´s nutritional status, the change of the serum prealbumin level at the day of the
      final study visit compared to baseline will represent the primary efficacy parameter in the
      present study. In addition, other variables will be assessed in this study, i.e.,
      postsurgical new onset of nosocomial infection, CRP, free fatty acids, immunology parameters,
      the results of physical examination, vital signs, relevant nutrition- and safety-related
      laboratory parameters in venous blood and urine, the results of an Electrocardiography (ECG),
      and the number, severity, seriousness, clinical relevance, relatedness and outcome of Adverse
      Events (AEs). The aim of the planned study is to demonstrate that SmofKabiven emulsion for
      infusion is not inferior to the comparative drug (hospital compounded &quot;All in one&quot; emulsion
      for parenteral nutrition).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2019</start_date>
  <completion_date type="Actual">January 23, 2020</completion_date>
  <primary_completion_date type="Actual">January 23, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Allocation to the treatment arms will not be known to the patient</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Prealbumin</measure>
    <time_frame>6 days</time_frame>
    <description>Change in Serum Prealbumin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nosocomial infection</measure>
    <time_frame>6 days</time_frame>
    <description>Postsurgical new onset of nosocomial infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prealbumin</measure>
    <time_frame>4 days</time_frame>
    <description>Change in Prealbumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein (CRP)</measure>
    <time_frame>6 days</time_frame>
    <description>Change in CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linoleic acid</measure>
    <time_frame>6 days</time_frame>
    <description>Change in linoleic acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linolenic acid</measure>
    <time_frame>6 days</time_frame>
    <description>Change in linolenic acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arachidonic acid</measure>
    <time_frame>6 days</time_frame>
    <description>Change in arachidonic acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eicosapentaenoic acid (EPA)</measure>
    <time_frame>6 days</time_frame>
    <description>Change in EPA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Docosahexaenoic acis (DHA)</measure>
    <time_frame>6 days</time_frame>
    <description>Change in DHA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboxane B3 (TX B3) / Thromboxane B2 (TX B2)</measure>
    <time_frame>6 days</time_frame>
    <description>Change in TX B3/B2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin (IL)-1</measure>
    <time_frame>6 days</time_frame>
    <description>Change in IL-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin (IL)-2</measure>
    <time_frame>6 days</time_frame>
    <description>Change in IL-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin (IL)-6</measure>
    <time_frame>6 days</time_frame>
    <description>Change in IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cluster of Differentiation 4 (CD4) / Cluster of Differentiation 8 (CD8)</measure>
    <time_frame>6 days</time_frame>
    <description>Change in CD4/CD8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma amino acid (taurine)</measure>
    <time_frame>6 days</time_frame>
    <description>Change in taurine</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Coded according to Medical Dictionary for Regulatory Affairs (MedDRA) by System Organ Class (SOC) and preferred term</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Vital signs</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Vital signs</description>
  </other_outcome>
  <other_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Vital signs</description>
  </other_outcome>
  <other_outcome>
    <measure>Axillary body temperature</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Vital signs</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of the head to detect significant medical aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of mouth to detect significant medical aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of the nose to detect significant medical aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of the throat to detect significant medical aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of the tonsils to detect significant medical aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of the eyes to detect significant medical aberrance (according to standard of care following the discretion of the treating physician)</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of the neck to detect significant medical aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of the lungs and chest to detect significant medical aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of the breasts to detect significant medical aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of the cardiovascular system to detect significant medical aberrance (according to standard of care following the discretion of the treating physician)</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of the abdomen to detect significant medical aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of the genitalia to detect significant medical aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of the musculoskeletal to detect significant medical aberrance (according to standard of care following the discretion of the treating physician)</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of the skin to detect significant medical aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of the neurological system to detect significant medical aberrance (according to standard of care following the discretion of the treating physician)</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of the lymph nodes to detect significant medical aberrance</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Examination of the ears to detect significant medical aberrance,</description>
  </other_outcome>
  <other_outcome>
    <measure>Red blood cell (RBC) count</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Total white blood cell (WBC) count</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Haemoglobin (Hb)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Haematocrit (Hct)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Platelets</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Creatinine</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Urea</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Sodium</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Potassium</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Magnesium</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Total calcium</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Chloride</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Phosphate</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Aspartate aminotransferase (AST)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Alanine aminotransferase (ALT)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Alkaline phosphatase (AP)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Gamma-glutamyl transpeptidase (Î³-GT)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Lactate dehydrogenase (LDH)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Total and direct bilirubin</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Albumin</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Total protein</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucose</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Cholesterol</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Triglycerides</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Low Density Lipoprotein (LDL)-C</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>High Density Lipoprotein (HDL)-C</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Fibrinogen</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Activated partial thromboplastin time (APTT)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Prothrombin time (PT)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>International Normalised Ratio (INR)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Laboratory variable</description>
  </other_outcome>
  <other_outcome>
    <measure>Power of water (pH) value</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Urine analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Bilirubin</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Urine analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Protein</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Urine analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>White Blood Cell (WBC)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Urine analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Red Blood Cell (RBC)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Urine analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucose</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Urine analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Ketone body</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Urine analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>up to 16 days</time_frame>
    <description>Electrocardiogram to assess cardiac disorders (e.g. Myocardial infarction, Pericarditis, QT interval Prolongation, etc.)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">273</enrollment>
  <condition>Parenteral Nutrition</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>SmofKabiven emulsion for infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SmofKabiven emulsion for infusion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drug is 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hospital compounded &quot;All in one&quot; emulsion for PN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hospital compounded &quot;All in one&quot; emulsion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drugs will be 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SmofKabiven emulsion for infusion</intervention_name>
    <description>Total Parenteral Nutrition</description>
    <arm_group_label>SmofKabiven emulsion for infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hospital compounded &quot;All in one&quot; emulsion</intervention_name>
    <description>Total Parenteral Nutrition</description>
    <arm_group_label>Hospital compounded &quot;All in one&quot; emulsion for PN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is scheduled to undergo elective gastrointestinal surgery;

          2. Female or male patients, age â¥ 18 and â¤ 80 years;

          3. Postoperatively, patient is expected to receive 100% of the total daily energy demand
             via PN for at least 5 consecutive days;

          4. Body Mass Index (BMI) â¥ 16 kg/m2 and â¤ 30 kg /m2, and actual body weight â¥ 40 kg;

          5. Patient is capable to give Informed Consent, agrees to participate in the study, and
             signs the Informed Consent Form.

        Exclusion Criteria:

          1. Patient has received PN or parenteral amino acids in the last 10 days before
             randomization (exception: administration of glucose will be allowed);

          2. Known severe liver insufficiency in the medical history, or AST or ALT at least
             3.0-times higher than the upper limit of normal range or total bilirubin at least
             1.5-times higher than the upper limit of normal range;

          3. International Normalised Ratio (INR) at least 1.5 times higher than the upper limit of
             normal range;

          4. Uncontrolled hyperglycaemia defined as fasting blood glucose &gt; 180 mg/ dl (10 mmol/L);

          5. Severe renal impairment defined as serum creatinine value at least 1.5 times higher
             than the upper limit of normal range;

          6. Serious hyperlipidaemia (serum cholesterol and/or triglycerides and/or LDL-C level at
             least 1.5 times higher than the upper limit of normal range);

          7. Known inborn abnormality of amino acid metabolism in the medical history;

          8. Known acute pancreatitis in the medical history;

          9. Known hypothyroidism or hyperthyroidism in the medical history;

         10. Serum level of any of the electrolytes (sodium, potassium, magnesium, total calcium,
             chloride, phosphate) above the upper limit of the normal range;

         11. Known unstable metabolism in the medical history (e.g., metabolic acidosis);

         12. Known hypersensitivity to fish, egg, soybean, or peanut protein or to any of the
             active substances or excipients of the study drugs in the medical history;

         13. General contraindications to infusion therapy: acute pulmonary oedema, hyperhydration,
             and decompensated cardiac insufficiency /congestive heart failure;

         14. Unstable haemodynamic conditions (e.g., acute myocardial infarction, stroke, embolism,
             severe sepsis, shock);

         15. Known hemophagocytic syndrome;

         16. Patients diagnosed with an infection before the surgery;

         17. Drug abuse and/or chronic alcoholism;

         18. Psychiatric diseases, epilepsy;

         19. Administration of growth hormones within the previous 4 weeks before surgery, or
             chronic maintenance therapy with systemic glucocorticoids 4 weeks before surgery;

         20. Participation in a clinical study with an investigational drug or an investigational
             medical device within one month prior to start of study or during study;

         21. Patient is pregnant or lactating and intends to continue breast-feeding;

         22. Development of intraoperative/ postoperative conditions (assessed after surgery and
             before enrolment of patients):

               1. Intra-operative blood loss &gt; 1000 ml;

               2. Development of a condition in which PN is contraindicated;

               3. Intra- or postoperative urine output &lt; 0.5 ml/kg/h;

               4. Need for postoperative haemofiltration or dialysis;

               5. Contraindication or inability to obtain central venous catheter access;

               6. Intra-operative decision on limited treatment, e.g. due to diagnosis of
                  carcinomatosis;

               7. Intra-operative severe complications including resuscitation, hemorrhagic and
                  septic shock, acute single and multiple organ dysfunction including pulmonary,
                  hepatic, and renal dysfunction prohibiting early postsurgical extubation,
                  requiring liver-specific treatment and renal replacement therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhang Zhongtao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thepeople's hospital of Guangxi zhuang</name>
      <address>
        <city>Nanning</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Pudong Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial People's Hospital</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002925.pdf</url>
    <description>International Council for Harmonisation (ICH) E10 'Note for Guidance on Choice of Control Group', July 2000</description>
  </link>
  <reference>
    <citation>Calder PC. n-3 fatty acids, inflammation, and immunity--relevance to postsurgical and critically ill patients. Lipids. 2004 Dec;39(12):1147-61. Review.</citation>
    <PMID>15736910</PMID>
  </reference>
  <reference>
    <citation>Mayer K, Gokorsch S, Fegbeutel C, Hattar K, Rosseau S, Walmrath D, Seeger W, Grimminger F. Parenteral nutrition with fish oil modulates cytokine response in patients with sepsis. Am J Respir Crit Care Med. 2003 May 15;167(10):1321-8. Epub 2003 Feb 25.</citation>
    <PMID>12615625</PMID>
  </reference>
  <reference>
    <citation>Novak TE, Babcock TA, Jho DH, Helton WS, Espat NJ. NF-kappa B inhibition by omega -3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol. 2003 Jan;284(1):L84-9. Epub 2002 Aug 30.</citation>
    <PMID>12388359</PMID>
  </reference>
  <reference>
    <citation>Pluess TT, Hayoz D, Berger MM, Tappy L, Revelly JP, Michaeli B, Carpentier YA, ChiolÃ©ro RL. Intravenous fish oil blunts the physiological response to endotoxin in healthy subjects. Intensive Care Med. 2007 May;33(5):789-797. doi: 10.1007/s00134-007-0591-5. Epub 2007 Mar 22. Erratum in: Intensive Care Med. 2007 Jul;33(7):1310. Intensive Care Med. 2007 Jul;33(7):1310.</citation>
    <PMID>17377770</PMID>
  </reference>
  <reference>
    <citation>Xiong J, Zhu S, Zhou Y, Wu H, Wang C. Regulation of omega-3 fish oil emulsion on the SIRS during the initial stage of severe acute pancreatitis. J Huazhong Univ Sci Technolog Med Sci. 2009 Feb;29(1):35-8. doi: 10.1007/s11596-009-0107-3. Epub 2009 Feb 18.</citation>
    <PMID>19224159</PMID>
  </reference>
  <reference>
    <citation>Helmut Grimm, A balanced lipid emulsionâA new concept in parenteral nutrition. Clinical Nutrition Supplements (2005) 1, 25-30.</citation>
  </reference>
  <reference>
    <citation>Grimm H, Mertes N, Goeters C, Schlotzer E, Mayer K, Grimminger F, FÃ¼rst P. Improved fatty acid and leukotriene pattern with a novel lipid emulsion in surgical patients. Eur J Nutr. 2006 Feb;45(1):55-60. Epub 2005 Jul 22.</citation>
    <PMID>16041475</PMID>
  </reference>
  <reference>
    <citation>Puder M, Valim C, Meisel JA, Le HD, de Meijer VE, Robinson EM, Zhou J, Duggan C, Gura KM. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg. 2009 Sep;250(3):395-402. doi: 10.1097/SLA.0b013e3181b36657.</citation>
    <PMID>19661785</PMID>
  </reference>
  <reference>
    <citation>Gura KM, Duggan CP, Collier SB, Jennings RW, Folkman J, Bistrian BR, Puder M. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006 Jul;118(1):e197-201.</citation>
    <PMID>16818533</PMID>
  </reference>
  <reference>
    <citation>Alwayn IP, Gura K, NosÃ© V, Zausche B, Javid P, Garza J, Verbesey J, Voss S, Ollero M, Andersson C, Bistrian B, Folkman J, Puder M. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005 Mar;57(3):445-52. Epub 2005 Jan 19.</citation>
    <PMID>15659701</PMID>
  </reference>
  <reference>
    <citation>BoulÃ©treau P, Chassard D, Allaouchiche B, Dumont JC, Auboyer C, Bertin-Maghit M, Bricard H, Ecochard R, Rangaraj J, Chambrier C, Schneid C, Cynober L. Glucose-lipid ratio is a determinant of nitrogen balance during total parenteral nutrition in critically ill patients: a prospective, randomized, multicenter blind trial with an intention-to-treat analysis. Intensive Care Med. 2005 Oct;31(10):1394-400. Epub 2005 Aug 24.</citation>
    <PMID>16132885</PMID>
  </reference>
  <reference>
    <citation>Sergi G, Coin A, Enzi G, Volpato S, Inelmen EM, Buttarello M, Peloso M, Mulone S, Marin S, Bonometto P. Role of visceral proteins in detecting malnutrition in the elderly. Eur J Clin Nutr. 2006 Feb;60(2):203-9.</citation>
    <PMID>16234837</PMID>
  </reference>
  <reference>
    <citation>Shenkin A. Serum prealbumin: Is it a marker of nutritional status or of risk of malnutrition? Clin Chem. 2006 Dec;52(12):2177-9.</citation>
    <PMID>17138848</PMID>
  </reference>
  <reference>
    <citation>Young GA, Hill GL. Assessment of protein-calorie malnutrition in surgical patients from plasma proteins and anthropometric measurements. Am J Clin Nutr. 1978 Mar;31(3):429-35.</citation>
    <PMID>415592</PMID>
  </reference>
  <reference>
    <citation>Young GA, Collins JP, Hill GL. Plasma proteins in patients receiving intravenous amino acids or intravenous hyperalimentation after major surgery. Am J Clin Nutr. 1979 Jun;32(6):1192-9.</citation>
    <PMID>87126</PMID>
  </reference>
  <reference>
    <citation>Young GA, Hill GL. A controlled study of protein-sparing therapy after excision of the rectum: effects of intravenous amino acids and hyperalimentation on body composition and plasma amino acids. Ann Surg. 1980 Aug;192(2):183-91.</citation>
    <PMID>6773484</PMID>
  </reference>
  <reference>
    <citation>Chinese medical clinical guidelines parenteral enteral nutrition 2008, edited by Chinese Medical Association, People's Medical Publishing House.</citation>
  </reference>
  <reference>
    <citation>Fresenius Kabi SSPC. Intralipid 20%, Summary of Product Characteristics, dated 14 February 2007.</citation>
  </reference>
  <reference>
    <citation>Bernstein LH. The systemic inflammatory response syndrome C-reactive protein and transthyretin conundrum. Clin Chem Lab Med. 2007;45(11):1566-7; author reply 1568-9.</citation>
    <PMID>17970714</PMID>
  </reference>
  <reference>
    <citation>Fresenius Kabi SSPC. Novamin 11.4%, Summary of Product Characteristics, dated 01 December 2013.</citation>
  </reference>
  <reference>
    <citation>McClave SA, Martindale RG, Vanek VW, McCarthy M, Roberts P, Taylor B, Ochoa JB, Napolitano L, Cresci G; A.S.P.E.N. Board of Directors; American College of Critical Care Medicine; Society of Critical Care Medicine. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2009 May-Jun;33(3):277-316. doi: 10.1177/0148607109335234.</citation>
    <PMID>19398613</PMID>
  </reference>
  <reference>
    <citation>Braga M, Ljungqvist O, Soeters P, Fearon K, Weimann A, Bozzetti F; ESPEN. ESPEN Guidelines on Parenteral Nutrition: surgery. Clin Nutr. 2009 Aug;28(4):378-86. doi: 10.1016/j.clnu.2009.04.002. Epub 2009 May 21.</citation>
    <PMID>19464088</PMID>
  </reference>
  <reference>
    <citation>Chowdary KV, Reddy PN. Parenteral nutrition: Revisited. Indian J Anaesth. 2010 Mar;54(2):95-103. doi: 10.4103/0019-5049.63637.</citation>
    <PMID>20661345</PMID>
  </reference>
  <reference>
    <citation>Singer P, Berger MM, Van den Berghe G, Biolo G, Calder P, Forbes A, Griffiths R, Kreyman G, Leverve X, Pichard C, ESPEN. ESPEN Guidelines on Parenteral Nutrition: intensive care. Clin Nutr. 2009 Aug;28(4):387-400. doi: 10.1016/j.clnu.2009.04.024. Epub 2009 Jun 7.</citation>
    <PMID>19505748</PMID>
  </reference>
  <reference>
    <citation>Fresenius Kabi. SomfKabiven emulsion for infusion. Summary of Product Characteristics, dated December 08. 2008.</citation>
  </reference>
  <reference>
    <citation>ZHAO Subin, GU Junxia, ZHANG Xianbin, SHI Dongfang, Early enteral nutrition with Fresubin after gastrointestinal operation, Parenteral&amp; Enteral Nutrition, Ju1ï¼2003, Vol l0 No.3: 134-136.</citation>
  </reference>
  <reference>
    <citation>Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Am J Infect Control. 1992 Oct;20(5):271-4.</citation>
    <PMID>1332552</PMID>
  </reference>
  <reference>
    <citation>Klevens RM, Edwards JR, Richards CL Jr, Horan TC, Gaynes RP, Pollock DA, Cardo DM. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 2007 Mar-Apr;122(2):160-6.</citation>
    <PMID>17357358</PMID>
  </reference>
  <reference>
    <citation>Wei Yi Fa (2001) No.2: Notice for Ministry of Health of China to Publish the Diagnosis Criteria of Nosocomial Infection (Pilot Edition). Ministry of Health of China Office, Jan.2, 200.</citation>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SmofKabiven</keyword>
  <keyword>Abdominal surgery</keyword>
  <keyword>Parenteral</keyword>
  <keyword>Nutrition</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

